Efficacy of RFA for Malignant Hilar Biliary Obstruction
| Study | No. | Technical success | No. of RFA session (range) | Stent | Complication early/late | Recurrent biliary obstruction | Patency (days) | Survival (days) |
|---|---|---|---|---|---|---|---|---|
| Inoue et al. (2020)71 | 41 | 39/41 (95.1) | 39 |
SBS, SEMS | 2.4/7.7 | 38.5 (15/39) | 230 | N/A |
| Bokemeyer et al. (2019)72 | 32 (21 hilar) | 100 | 54 |
Plastic 85.2%, SEMS 14.8% | 10/54 (18.5) | N/A | N/A | 342/221 (control; p=0.046) |
| Tal et al. (2014)73 | 12 | 100 | 19 |
Plastic | Late bleeding 3 Cholangitis 4 |
N/A | N/A | 6.4 m |
| Kim et al. (2019)74 | 11 | 100 | 4 |
Plastic, SEMS | Early; pancreatitis (1), fever only (5) | 27.3 (3) | 30-day stent patency (100%) | 191 |
| Schmidt et al. (2016)75 | 14 | 100 | 31 |
Plastic, SEMS | 28 (4); cholangitis, liver abscess, sepsis | Premature stent replacements (<3 m), 29 (4) | N/A | N/A |
Values are presented the number/number (%).
RFA, radiofrequency ablation; SEMS, self-expandable metal stent; N/A, not available; SBS, stent-by-stent.
aHabibTM EndoHPB Biopolar Radiofrequency Catheter (Boston Scientific, Marlborough, USA; EMcision UK, London, United Kingdom);
bTemperature-controlled ID-RFA catheter (ELRA; STARmed, Goyang, Korea) and RF generator (VIVA Combo; STARmed).